Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B‐cell lymphoma

Summary Whether or not bone marrow biopsies should be performed routinely in patients with skin lesions that show histological features consistent with an indolent B‐cell lymphoma [marginal zone lymphoma (MZL) or follicle centre lymphoma (FCL)] has been debated. As no studies have addressed this que...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2008-07, Vol.142 (1), p.52-56
Main Authors: Senff, Nancy J., Kluin‐Nelemans, Hanneke C., Willemze, Rein
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biopsy
Bone Marrow - pathology
bone marrow biopsy
Bone Marrow Examination
cutaneous B‐cell lymphoma
Female
Hematologic and hematopoietic diseases
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, B-Cell - mortality
Lymphoma, B-Cell - pathology
Lymphoma, B-Cell, Marginal Zone - mortality
Lymphoma, B-Cell, Marginal Zone - pathology
Male
Medical sciences
Middle Aged
Neoplasm Staging
Prognosis
skin
Skin Neoplasms - mortality
Skin Neoplasms - pathology
staging
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Whether or not bone marrow biopsies should be performed routinely in patients with skin lesions that show histological features consistent with an indolent B‐cell lymphoma [marginal zone lymphoma (MZL) or follicle centre lymphoma (FCL)] has been debated. As no studies have addressed this question for this group of lymphomas, we evaluated the results of bone marrow biopsy examination in 275 patients with histological features consistent with MZL (n = 82) or FCL (n = 193) first presenting in the skin. In the MZL group, two of 82 patients (2%) showed bone marrow involvement, which was the only extracutaneous localization in one of these patients. In the FCL group, 22 of 193 patients (11%) had bone marrow involvement and was the only extracutaneous localization in nine of them. FCL patients with skin lesions and a positive bone marrow had a significantly worse prognosis when compared with patients with only skin lesions (5‐year disease‐specific survival 63% vs. 95%; P = 0·001). These results indicate that bone marrow investigation is essential for staging patients with a FCL first presenting in the skin. Bone marrow examination appears to have limited value in patients with MZL presenting in the skin.
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2008.07159.x